drugset

drugset / Trial / NCT02420392

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

NCT02420392 ↗

Completed 30 enrolled Seoul National University Hospital AstraZeneca · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.

Timeline

Start: 2015-02
Primary completion: 2016-04
Completion: 2016-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	—	—

Indications